# US 9,750,715 B2 · Method of reversing, preventing, delaying or stabilizing soft tissue calcification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,715 B2
- Document ID: US9750715B2
- Status: Granted
- Kind: B2
- Application number: 12/162,558
- Filed: 2007-01-26
- Published: 2009-12-31
- Granted: 2017-09-05
- Earliest claimed: 2006-01-30
- Assignees: Panion & Biotech Inc.
- Applicants: Keith Chan; Winston Town; Shou Shan Chiang
- Inventors: Keith Chan; Winston Town; Shou Shan Chiang
- Web page: https://patentgrep.com/patent/US9750715B2

## CPC

- A61K 31/295: Iron group metal compounds
- A61K 9/143: {with inorganic compounds}
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 33/26: Iron; Compounds thereof
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/12: for electrolyte homeostasis
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 5/18: of the parathyroid hormones
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 27/02: Ophthalmic agents
- A61P 39/00: General protective or antinoxious agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods of treating soft tissue calcification in a subject, comprising a step of administering to said subject an effective amount of ferric organic compound, such as ferric citrate. The claimed methods may prevent, reverse, delay or stabilize soft tissue calcification in a subject having chronic kidney disease. Affected soft tissue calcification includes soft tissue calcification in the joint, skin, eye, in cardiovascular system such as heart valve, myocardium, coronary arteries and arteriole, or in internal organs such as kidney and lung.

## Claims

### Claim 1

A method of reversing soft tissue calcification in a subject, comprising administering to said subject an effective amount of ferric citrate having a dissolution rate of at least 2 mg/cm2/min, wherein soft tissue calcification is reversed.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ferric citrate has a dissolution rate from about 2 mg/cm2/min to about 4 mg/cm2/min.

### Claim 3 (depends on 1)

The method of claim 1, wherein the soft tissue is selected from soft tissue in a joint, the skin, an eye, a heart valve, the myocardium, a coronary artery, a coronary arteriole, a kidney and a lung.

### Claim 4 (depends on 3)

The method of claim 3, wherein the soft tissue is eye tissue.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ferric citrate is formulated for oral administration.

### Claim 6 (depends on 5)

The method of claim 5, wherein the ferric citrate is formulated as a tablet, a powder, a suspension, an emulsion, a capsule, a lozenge, a granule, a troche, a pill, a liquid, a spirit or a syrup.

### Claim 7 (depends on 1)

The method of claim 1, wherein the effective amount of ferric citrate is 2 grams per day.

### Claim 8 (depends on 1)

The method of claim 1, wherein the effective amount of ferric citrate is 4 grams per day.

### Claim 9 (depends on 1)

The method of claim 1, wherein the effective amount of ferric citrate is 6 grams per day.

### Claim 10 (depends on 1)

The method of claim 1, wherein calcification is reversed by up to 40%.

### Claim 11 (depends on 1)

The method of claim 1, wherein calcification is reversed by up to 56%.

### Claim 12 (depends on 1)

The method of claim 1, wherein calcification is reversed by up to 67%.

### Claim 13 (depends on 1)

The method of claim 1, wherein calcification is reversed by up to 100%.